Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application

Table 2 Prognostic effects of different TLS characteristics on different disease types

TLS features		Disease types	Methodology	Prognostic value	Experimental Subject	References
Quantity and density	High TLS density	iCCA	mIHC	Positive	Patients	[16]
	High TLS density	HCC	IHC	Positive	Patients	[106]
	Quantity	Non-functional Pancreatic neuroendocrine tumours	H&E IHC	No prognostic significance	Patients	[16]
Locations	Intra-tumoral	iCCA	mIHC	Positive	Patients	[16]
		CRC liver metastases	mIHC	Positive	Patients	[104]
		HCC	H&E IHC	Positive	patients	[49]
	Peritumoral	iCCA	mIHC	Negative	Patients	[16]
		Melanoma	mIHC	Positive	Patients	[107]
		HCC	H&E IHC	No prognostic significance	patients	[49]
Molecular or tissue characteristics	CXCL13	Bladder cancer	RNA seq	Positive	Patients	[108]
	CXCL13	Influenza A virus	Flow cytometry	Positive	Mice	[109]
	IL-22, IL-23	Crohn’s disease	H&E, RNA seq, Flow cytometry	Positive	Mice	[110]
	HEV	BC	IHC	Positive	patients	[49]
	ND	Bladder cancer	IHC	Positive	patients	[111]
	CD153/CD30	Chronic kidney disease	Flow cytometry, RNA seq	Negative	Mice	[82]
	CD153/CD30	Endothelial notch signaling	RNA seq, Flow cytometry, IF	Negative	Mice	[112]

mIHC: Multiplex immunohistochemistry; IHC: Immunohistochemistry; H&E: Hematoxylin and eosin staining; RNA seq: RNA sequencing; IF: Immunofluorescence

ISSN: 1476-4598